CEL-SCI (FRA:LSR) Shiller PE Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LSR CEL-SCI Corp FRA:LSR
30 GF Score
Price €1.24
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CEL-SCI  (FRA:LSR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CEL-SCI Shiller PE Ratio Related Terms


CEL-SCI Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for CEL-SCI's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI Shiller PE Ratio Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CEL-SCI Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:LSR vs HOWL, ZIVO, MRKR: Shiller PE Ratio Comparison

For the Biotechnology subindustry, CEL-SCI's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Shiller PE Ratio falls into.


FRA:LSR
30GF Score
CEL-SCI Corp FRA:LSR
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CEL-SCI's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, CEL-SCI's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.408/333.9520*333.9520
=-0.408

Current CPI (Jun. 2026) = 333.9520.

CEL-SCI Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -4.277 241.428 -5.916
201612 9.101 241.432 12.589
201703 -32.257 243.801 -44.185
201706 -14.151 244.955 -19.292
201709 -14.347 246.819 -19.412
201712 -13.435 246.524 -18.200
201803 -7.542 249.554 -10.093
201806 -9.245 251.989 -12.252
201809 -17.997 252.439 -23.808
201812 0.527 251.233 0.701
201903 -5.841 254.202 -7.673
201906 -9.824 256.143 -12.808
201909 -3.541 256.759 -4.606
201912 -4.320 256.974 -5.614
202003 -6.787 258.115 -8.781
202006 -7.193 257.797 -9.318
202009 -3.311 260.280 -4.248
202012 -5.179 260.474 -6.640
202103 -7.056 264.877 -8.896
202106 -6.225 271.696 -7.651
202109 -4.845 274.310 -5.898
202112 -5.310 278.802 -6.360
202203 -6.265 287.504 -7.277
202206 -6.527 296.311 -7.356
202209 -6.363 296.808 -7.159
202212 -5.098 296.797 -5.736
202303 -5.324 301.836 -5.890
202306 -5.261 305.109 -5.758
202309 -4.498 307.789 -4.880
202312 -3.851 306.746 -4.193
202403 -3.864 312.332 -4.131
202406 -3.883 314.175 -4.127
202409 -2.523 315.301 -2.672
202412 -3.104 315.605 -3.284
202503 -2.155 319.799 -2.250
202506 -1.179 322.561 -1.221
202509 -0.648 324.800 -0.666
202512 -0.581 324.054 -0.599
202603 -0.580 330.213 -0.587
202606 -0.408 333.952 -0.408

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
30GF Score

Get the complete analysis for FRA:LSR

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.24
Price